GlassScriptPhysician profile
Sripathi R Kethu
NPI 1801840111
$7,914.27
in general payments reported to CMS, 2019-2025
38 companies · $1,764 in 2025
The $1,764 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,010 · 2020: $479 · 2021: $768 · 2022: $955 · 2023: $988 · 2024: $1,950 · 2025: $1,764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,655 · Education: $47.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,655.22 |
| Education | $47.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,863.06 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $773.04 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $662.60 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Merck Sharp & Dohme LLC | $379.67 | 2019-2024 | Dificid, Zerbaxa, Recarbrio |
| Genzyme Corporation | $348.76 | 2022-2025 | |
| Pfizer INC. | $336.32 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $260.06 | 2019-2025 | Trulance, Xifaxan |
| Celgene Corporation | $232.01 | 2022-2024 | Zeposia |
| Boston Scientific Corporation | $217.04 | 2019-2024 | |
| Ardelyx, INC. | $181.20 | 2022-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $167.25 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $160.02 | 2019-2024 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $145.45 | 2023-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $139.37 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $103.01 | 2019-2025 | Sucraid, Sucraid |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $95.50 | 2019-2023 | |
| Allergan, INC. | $83.92 | 2019-2020 | |
| Celltrion USA INC. | $83.21 | 2024-2025 | Vegzelma, Zymfentra |
| Lilly USA, LLC | $81.09 | 2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $76.88 | 2019-2023 | Linzess |
| Ferring Pharmaceuticals INC. | $70.75 | 2022-2023 | Clenpiq, Rebyota |
| Redhill Biopharma INC. | $59.87 | 2020-2021 | |
| Aimmune Therapeutics, INC. | $57.87 | 2025 | Zenpep, Vowst |
| American Regent | $48.21 | 2024 | Injectafer |
| Braintree Laboratories, INC. | $33.56 | 2019-2021 | |
| Medtronic, INC. | $29.15 | 2022 | |
| Evoke Pharma, INC. | $27.66 | 2021-2022 | |
| Daiichi Sankyo INC. | $26.43 | 2019-2020 | |
| Shionogi INC | $23.47 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $21.69 | 2025 | Eyemax |
| Mauna Kea Technologies, INC. | $20.80 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $18.71 | 2025 | Iqirvo |
| Abbott Laboratories | $18.04 | 2019 | |
| Novo Nordisk INC | $17.62 | 2025 | Wegovy |
| Ethicon US, LLC | $17.59 | 2019 | |
| Covidien LP | $17.44 | 2020 | |
| Enterra Medical, INC. | $15.95 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$48,130.75 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sripathi Kethu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.